LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc VRP VRNA ("Verona Pharma"), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce the appointment of Nplus1 Singer Advisory LLP (together with its associates, "N+1 Singer") as nominated adviser and UK corporate broker to the Company with immediate effect.
For further information contact:
Verona Pharma plc Jan-Anders Karlsson, Chief Executive Officer Victoria Stewart, Director of Communications | Tel: +44 (0)20 3283 4200 info@veronapharma.com |
N+1 Singer (Nominated Adviser and UK Broker) Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) Mia Gardner (Corporate Broking) | Tel: +44 (0)20 7496 3000 |
ICR, Inc. (US Media and Investor enquiries) Darcie Robinson Stephanie Carrington | Tel: +1 203-919-7905 Darcie.Robinson@icrinc.com Tel. +1 646-277-1282 Stephanie.Carrington@icrinc.com |
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma is also developing ensifentrine for the treatment of cystic fibrosis and asthma.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.